{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:32:05Z","timestamp":1760131925102},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"unspecified","delay-in-days":10711,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Law Med. Health Care"],"published-print":{"date-parts":[[1992]]},"abstract":"<jats:p>RU <jats:sub>4<\/jats:sub>86 is a synthetic drug with antisteroid hormone properties, synthesized by the Roussel-Uclaf Company, Paris, France, which owns a world-wide patent for all uses.<\/jats:p><jats:p>I have summarized the story of RU <jats:sub>4<\/jats:sub>86's discovery, testing and use in the <jats:italic>Journal of the American Medical Association,<\/jats:italic> in <jats:italic>Science?<\/jats:italic> and in a book entitled <jats:italic>The Abortion Pill,<\/jats:italic> also published in French as <jats:italic>G\u00e9n\u00e9ration Pilule.<\/jats:italic><\/jats:p><jats:p>Based on antiprogesterone action, RU <jats:sub>4<\/jats:sub>86 was first approved in France for voluntary pregnancy interruption (VIP), within the framework of the abortion law, as a medical method to replace the instrumental technique in use when the law was passed in 1975. Registration of RU <jats:sub>4<\/jats:sub>86 was obtained in September 1988.<\/jats:p>","DOI":"10.1111\/j.1748-720x.1992.tb01182.x","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T12:30:38Z","timestamp":1181046638000},"page":"154-156","source":"Crossref","is-referenced-by-count":2,"title":["Updating RU <sub>4<\/sub>86 Development"],"prefix":"10.1017","volume":"20","author":[{"given":"Etienne-Emile","family":"Baulieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"S0277845900017425_ref8","unstructured":"8. Prostaglandins are local hormones which are naturally involved in contractions of the uterus during delivery and abortion and physiologically help expulsion."},{"key":"S0277845900017425_ref12","first-page":"539","article-title":"\u201cActivit\u00e9 contragestive de l'association au RU 486 d'une prostaglandine active par voie orale\u201d","volume":"312","author":"Aub\u00e9ny","year":"1991","journal-title":"CR Acadm. Sci. Paris"},{"key":"S0277845900017425_ref5","unstructured":"5. Progesterone is a steroid hormone indispensable for the beginning and the continuation of pregnancy."},{"key":"S0277845900017425_ref10","unstructured":"10. Dr. Bygdeman, M."},{"key":"S0277845900017425_ref23","unstructured":"23. Objective: A baby in better health."},{"key":"S0277845900017425_ref15","unstructured":"15. Registration on July 1st, 1991."},{"key":"S0277845900017425_ref26","unstructured":"26. See supra note 2."},{"key":"S0277845900017425_ref14","unstructured":"14. It was proposed to decrease RU 486 dosage when associated with Sulprostone or Gemeprost; however these prostaglandins were given at probably larger than adequate doses, and the data presented so far are irrelevant to the use of Misoprostol."},{"key":"S0277845900017425_ref6","unstructured":"6. Three containing each 200 mg of RU 486 and taken together."},{"key":"S0277845900017425_ref2","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.1989.03430130084039","article-title":"\u201cRU 486 as an Antiprogesterone Steroid: From Receptor to Contragestion and Beyond,\u201d","volume":"262","year":"1989","journal-title":"J.A.M.A."},{"key":"S0277845900017425_ref4","volume-title":"The Abortion Pill","author":"Odile","year":"1991"},{"key":"S0277845900017425_ref20","first-page":"401","volume-title":"International Protection of Women's Reproductive Rights","volume":"24","author":"Cook","year":"1992"},{"key":"S0277845900017425_ref24","unstructured":"24. With Cushing syndromes, meningiomas."},{"key":"S0277845900017425_ref13","doi-asserted-by":"crossref","unstructured":"13. Norman, J.E. , Thong, K.J. , Baird, D.T. , \u201cUterine Contractility and Induction of Abortion in Early Pregnancy by Misoprostol and Mifepristone\u201d, 338 The Lancet 1233\u20131236 (1991).","DOI":"10.1016\/0140-6736(91)92102-8"},{"key":"S0277845900017425_ref9","unstructured":"9. 95 percent or more complete successes."},{"key":"S0277845900017425_ref21","unstructured":"21. There is no predictable fetal abnormality, but there is no reason to take an additional risk."},{"key":"S0277845900017425_ref16","unstructured":"16. New York."},{"key":"S0277845900017425_ref18","unstructured":"18. Frankfurt."},{"key":"S0277845900017425_ref7","unstructured":"7. Time of optimal antiprogesterone activity."},{"key":"S0277845900017425_ref19","unstructured":"19. HRPI."},{"key":"S0277845900017425_ref3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.2781282","article-title":"\u201cContragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the Receptor,\u201d","volume":"245","year":"1989","journal-title":"Science"},{"key":"S0277845900017425_ref11","unstructured":"11. A PG-E2 derivative."},{"key":"S0277845900017425_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(88)90102-3"},{"key":"S0277845900017425_ref1","unstructured":"1. Generic name Mifepristone, trade name in France and the U.K. Mifegyne."},{"key":"S0277845900017425_ref22","unstructured":"22. Registration just obtained in France."},{"key":"S0277845900017425_ref27","unstructured":"27. We should be free to have different opinions about this, just as we do about the future of a human being after death."},{"key":"S0277845900017425_ref17","unstructured":"17. Signed in 1982, and remaining valid."}],"container-title":["Law, Medicine and Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1748-720X.1992.tb01182.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1111\/j.1748-720X.1992.tb01182.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0277845900017425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T11:59:19Z","timestamp":1619697559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0277845900017425\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1992]]}},"alternative-id":["S0277845900017425"],"URL":"https:\/\/doi.org\/10.1111\/j.1748-720x.1992.tb01182.x","relation":{},"ISSN":["0277-8459","2151-7878"],"issn-type":[{"value":"0277-8459","type":"print"},{"value":"2151-7878","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992]]}}}